
primary studies - congress abstract

Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: a Randomized, Double-Blind, Placebo-Controlled Phase 3b Study

Code: CN-XXXXX011 **Year:** 2019 **Date:** 2019

Author: Schwarz C

See also

Pneumologie (Stuttgart, Germany), 2019, 73(SUPPL. 1)

Keywords

Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; lumacaftor; Orkambi; Symdeko; Symkevi;